Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Bright Bloom Crossbody Bag
Popular Articles

Study Provides Documentation That Tumor "Stem-like Cells" Exist In Benign Tumors
Cancer stem-like cells have been implicated in the genesis of a variety of malignant cancers. Research scientists at Cedars-Sinai Medical Center"s Maxine Dunitz Neurosurgical Institute have isolated stem-like cells in benign (pituitary) tumors and used these "mother" cells to generate new tumors in laboratory mice. Targeting the cells of origin is seen as a possible strategy in the fight against malignant and benign tumors.

Interim Study Results Presented At ADA 2009: Exenatide Not Associated With Increased Rate Of Acute Pancreatitis Compared To Other Antidiabetic Drugs
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) announced interim results from a retrospective study including nearly 260,000 patients that showed the risk of acute pancreatitis among patients initiating therapy with BYETTA(R) (exenatide) injection was not increased compared to patients initiating other antidiabetic therapies. These findings were presented at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA) in New Orleans.
News of the day
Oculus Innovative Sciences Announces Preliminary Results From 40-Patient Feasibility Study For Treatment Of Acne With The Microcyn(R) Technology
Oculus Innovative Sciences, Inc. (Nasdaq: OCLS), a healthcare company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, announced that preliminary results from its U.S. 40-patient feasibility study, in which an enhanced formulation of the company"s Microcyn Technology-based hydrogel was used in the treatment of acne, are highly encouraging and warrant further examination.
Endocrinology

Boston Scientific Announces European Approval For Its Latitude(R) Patient Management System

Boston Scientific Corporation (NYSE: BSX) announced CE Mark for its LATITUDE® Patient Management system. The LATITUDE system remotely monitors patients with implantable cardiac devices, gathering information on both the device and a patient"s heart health status. The system can also detect clinical events between scheduled physician visits and send relevant data directly to a patient"s physician. It will be launched in Europe in a phased approach beginning this week. "The wireless LATITUDE system will enable me to more closely monitor my patients while helping manage hospital workflow," said Konstantin M. Heinroth, M.D., Department of Medicine, Martin Luther-University Halle-Wittenberg, Halle, Germany. "I hope to provide my patients added convenience and the peace of mind that comes from knowing both their device and heart health status can be monitored." "Boston Scientific has enrolled more than 130,000 patients on the LATITUDE system since its introduction in the U.S. in 2006, making it the most rapidly adopted remote cardiac device monitoring system in the industry[1]," said Fred Colen, President, Boston Scientific Cardiac Rhythm Management. "We expect continued success as we introduce the demonstrated benefits of our LATITUDE system to patients and physicians in Europe. Remote monitoring technology provides a significant opportunity to further improve patient care." The LATITUDE system provides physicians actionable information that enables them to see changes in their patient"s cardiac health sooner than regularly scheduled follow-up visits. LATITUDE is the only remote cardiac device monitoring system with an optional wireless weight scale and blood pressure monitor, both of which are recommended by the European Society of Cardiology for the management of Class I heart failure patients. The international version of the LATITUDE system is compatible with the Company"s wireless TELIGEN® implantable cardioverter defibrillator (ICD) and COGNIS® cardiac resynchronization therapy defibrillator (CRT-D), the world"s smallest and thinnest high-energy devices. The first enrollments of European patients onto the LATITUDE system were performed by Dr. J.H. Ruiter at Medisch Centrum Hospital, Alkmaar, Netherlands and Dr. Peter Mortensen, Skejby University Hospital, Aarhus, Denmark. [1] Data based on number of patients at three years post-launch. Data on file. Boston Scientific


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009